ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma

Source: Pharmacy Times articles

A new study reveals the combination therapy enhances safety and efficacy for high-risk BRAF-mutated stage II melanoma.
Read More